Magnetic stimulation reduces compulsive behaviors
- Trial ID
- NCT06237868
- Official Title
- The Effects of High-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Control Disorders in Parkinson's Disease Patients on Dopamine Replacement Therapy.
- Goal
- Magnetic stimulation reduces compulsive behaviors
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- West Virginia University
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Impulse Control Disorder, Parkinson Disease
- Interventions
- rTMS Active, rTMS Sham
Plain-Language Summary
The goal is to reduce impulse control problems like gambling, compulsive shopping, hypersexuality, punding, or dopamine dysregulation syndrome that can arise while on dopamine replacement therapy. The approach uses high-frequency repetitive transcranial magnetic stimulation, sending repeated magnetic pulses to boost activity in frontal brain regions involved in self-control, such as the dorsolateral prefrontal cortex, with active stimulation compared to a sham procedure, and it does not change your levodopa or other dopamine meds. Adults 18 and older with clinician-confirmed Parkinson's who are on dopamine-replacement therapy and have clinician-diagnosed impulse control behaviors can enroll, provided they have mild or no depression (BDI ≤14), reasonable cognition (MoCA ≥20), and no seizure history, major psychiatric illness, significant brain lesions or recent TMS, pregnancy, intracranial metal, or medications that raise seizure risk.
Locations
- West Virginia University Hospitals, Morgantown, West Virginia, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying rTMS Active. The goal is to reduce impulse control problems like gambling, compulsive shopping, hypersexuality, punding, or dopamine dysregulation syndrome that can arise while on dopamine replacement therapy. The approach uses high-frequency repetitive transcranial magnetic stimulation, sending repeated magnetic pulses to boost activity in frontal brain regions involved in self-control, such as the dorsolateral prefrontal cortex, with active stimulation compared to a sham procedure, and it does not change your levodopa or other dopamine meds. Adults 18 and older with clinician-confirmed Parkinson's who are on dopamine-replacement therapy and have clinician-diagnosed impulse control behaviors can enroll, provided they have mild or no depression (BDI ≤14), reasonable cognition (MoCA ≥20), and no seizure history, major psychiatric illness, significant brain lesions or recent TMS, pregnancy, intracranial metal, or medications that raise seizure risk.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.